Annika Auranen

7.2k total citations
72 papers, 1.6k citations indexed

About

Annika Auranen is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Annika Auranen has authored 72 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Reproductive Medicine, 23 papers in Obstetrics and Gynecology and 21 papers in Oncology. Recurrent topics in Annika Auranen's work include Ovarian cancer diagnosis and treatment (46 papers), Endometrial and Cervical Cancer Treatments (21 papers) and Intraperitoneal and Appendiceal Malignancies (12 papers). Annika Auranen is often cited by papers focused on Ovarian cancer diagnosis and treatment (46 papers), Endometrial and Cervical Cancer Treatments (21 papers) and Intraperitoneal and Appendiceal Malignancies (12 papers). Annika Auranen collaborates with scholars based in Finland, Denmark and United States. Annika Auranen's co-authors include Seija Grénman, Olli Carpén, Johanna Hynninen, Seija Grénman, Sinikka Oksa, Maija Lavonius, Kaisa Huhtinen, Marko Seppänen, Jutta Huvila and Jukka Kemppainen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Annika Auranen

68 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annika Auranen Finland 23 930 492 385 376 316 72 1.6k
Gina Mantia-Smaldone United States 19 758 0.8× 353 0.7× 271 0.7× 487 1.3× 751 2.4× 56 1.8k
W. Schröder Germany 18 576 0.6× 470 1.0× 356 0.9× 299 0.8× 274 0.9× 57 1.3k
Wataru Yamagami Japan 24 703 0.8× 763 1.6× 212 0.6× 473 1.3× 641 2.0× 124 2.0k
Darren Wheeler United States 15 560 0.6× 397 0.8× 285 0.7× 167 0.4× 262 0.8× 30 1.1k
Soon‐Beom Kang South Korea 24 692 0.7× 778 1.6× 223 0.6× 277 0.7× 354 1.1× 64 1.5k
A Fanucchi Italy 24 833 0.9× 631 1.3× 390 1.0× 267 0.7× 420 1.3× 64 1.6k
Jacob Korach Israel 24 886 1.0× 565 1.1× 222 0.6× 311 0.8× 567 1.8× 107 1.6k
Antonio Santillan United States 21 880 0.9× 469 1.0× 676 1.8× 440 1.2× 290 0.9× 27 1.6k
S. Pecorelli Italy 4 895 1.0× 460 0.9× 456 1.2× 224 0.6× 284 0.9× 4 1.2k
Noh-Hyun Park South Korea 29 869 0.9× 1.1k 2.1× 297 0.8× 398 1.1× 441 1.4× 77 2.1k

Countries citing papers authored by Annika Auranen

Since Specialization
Citations

This map shows the geographic impact of Annika Auranen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annika Auranen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annika Auranen more than expected).

Fields of papers citing papers by Annika Auranen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annika Auranen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annika Auranen. The network helps show where Annika Auranen may publish in the future.

Co-authorship network of co-authors of Annika Auranen

This figure shows the co-authorship network connecting the top 25 collaborators of Annika Auranen. A scholar is included among the top collaborators of Annika Auranen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annika Auranen. Annika Auranen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kallio, Heini, Synnöve Staff, Kati Kivinummi, et al.. (2024). Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer. Life Science Alliance. 7(6). e202402658–e202402658. 7 indexed citations
4.
Auranen, Annika, Lyndsay Willmott, David Cibula, et al.. (2024). 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups. ESMO Open. 9. 103537–103537. 3 indexed citations
5.
Leskelä, Riikka‐Leena, J Idänpään-Heikkilä, B. Mascialino, et al.. (2024). Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study. Acta Oncologica. 63. 763–771. 2 indexed citations
6.
7.
Soini, Erkki, Christian Asseburg, Tuomo J Meretoja, et al.. (2024). EE345 Lifetime Cost-Effectiveness of Hereditary Breast and Ovarian Cancer Prevention Based on FinnGen and Biobank Data, Data Returning Process, and Prophylaxis. Value in Health. 27(6). S120–S121.
8.
Mirza, Mansoor R., Line Bjørge, Frederik Marmé, et al.. (2024). Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecologic Oncology. 192. 128–136. 3 indexed citations
9.
Heuser, Vanina D., Swapnil Potdar, Jaana Oikkonen, et al.. (2022). Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Frontiers in Oncology. 12. 954430–954430. 11 indexed citations
10.
Tomás, Eija, et al.. (2021). Decreasing trend and changing indications of hysterectomy in Finland. Acta Obstetricia Et Gynecologica Scandinavica. 100(9). 1722–1729. 17 indexed citations
11.
Hynninen, Johanna, Tuulia Vallius, Jukka Kemppainen, et al.. (2018). Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer. Clinical Oncology. 30(8). 507–514. 6 indexed citations
12.
Huhtinen, Kaisa, et al.. (2018). The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer. Oncology. 94(4). 233–242. 17 indexed citations
13.
Lindemann, Kristina, Emma Gibbs, Elisabeth Åvall‐Lundqvist, et al.. (2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer. 116(4). 455–463. 36 indexed citations
14.
Chen, Ping, Kaisa Huhtinen, Katja Kaipio, et al.. (2015). Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy. Cancer Research. 75(15). 2987–2998. 30 indexed citations
15.
Huvila, Jutta, Lauri Talve, Olli Carpén, et al.. (2013). Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecologic Oncology. 130(3). 463–469. 37 indexed citations
16.
Auranen, Annika, Markku Kallajoki, Maija Lavonius, & Paula Lindholm. (2012). [Mesenterial fibrosis--could it be desmoidi?].. PubMed. 128(24). 2562–8. 1 indexed citations
17.
Auranen, Annika, Sakari Hietanen, Teea Salmi, & Seija Grénman. (2005). Hormonal treatments and epithelial ovarian cancer risk. International Journal of Gynecological Cancer. 15(5). 692–700. 14 indexed citations
18.
Auranen, Annika, et al.. (2004). 629 Impact of Hemoglobin Levels on The Outcome of Ovarian Cancer. International Journal of Gynecological Cancer. 14. 175–175. 1 indexed citations
19.
Auranen, Annika & L Iselius. (1998). Segregation analysis of epithelial ovarian cancer in Finland. British Journal of Cancer. 77(9). 1537–1541. 4 indexed citations
20.
Auranen, Annika, Seija Grénman, J Mäkinen, et al.. (1996). Borderline Ovarian Tumors in Finland: Epidemiology and Familial Occurrence. American Journal of Epidemiology. 144(6). 548–553. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gina Mantia-Smaldone Breakdown of academic impact, for papers by W. Schröder Breakdown of academic impact, for papers by Wataru Yamagami Breakdown of academic impact, for papers by Darren Wheeler Breakdown of academic impact, for papers by Soon‐Beom Kang Breakdown of academic impact, for papers by A Fanucchi Breakdown of academic impact, for papers by Jacob Korach Breakdown of academic impact, for papers by Antonio Santillan Breakdown of academic impact, for papers by S. Pecorelli Breakdown of academic impact, for papers by Noh-Hyun Park
Rankless by CCL
2026